Document type
ArticleVersion
Accepted versionPublication date
All rights reserved
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/160529
Commercially approved vaccines for canine leishmaniosis: a review of available data on their safety and efficacy
Journal Title
Director/Tutor
Journal ISSN
Volume Title
Related resource
Abstract
Canine leishmaniosis is an important vector-borne zoonosis caused mainly by Leishmania infantum. Diagnosis and treatment of affected individuals can be particularly complex, hindering infection control in endemic areas. Methods to prevent canine leishmaniosis include the use of topical insecticides, prophylactic immunotherapy and vaccination. Four vaccines against canine leishmaniosis have been licensed since 2004, two in Brazil (Leishmune®, the production and marketing license of which was withdrawn in 2014, and Leish-Tec®) and two in Europe (CaniLeish® and LetiFend®). After several years of marketing, doubts remain regarding vaccine efficacy and effectiveness, potential infectiousness of vaccinated and infected animals or the interference of vaccine-induced antibodies in L. infantum serological diagnosis. This review summarizes the scientific evidence for each of the vaccines commercially approved for canine leishmaniosis, while discussing possible weaknesses of these studies. Furthermore, it raises the need to address important questions related to vaccination impact in Leishmania-endemic countries and the importance of post-marketing pharmacological surveillance.
Subject
Subject (English)
Citation
Citation
VÉLEZ, Rita and GÁLLEGO CULLERÉ, M. (Montserrat). Commercially approved vaccines for canine leishmaniosis: a review of available data on their safety and efficacy. Tropical Medicine & International Health. 2020. Vol. 25, num. 5, pags. 540-557. ISSN 1360-2276. [consulted: 19 of August of 2026]. Available at: https://hdl.handle.net/2445/160529